IRCT20200105046010N97尚未招募Unknown
In-vivo Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg Kharazmi Pharma Co Tablets of The Test Drug in Compared with The Reference Drug (GLYXAMBI® Tab 25/5 mg. Beohringer Ingelheim Germany) In Healthy Volunteers
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Empagliflozin or linagliptin
研究者
相似试验
尚未招募
不适用
Empagliflozin, Linagliptin tablet 25, 5mg ABIDI (Glorenta 25, 5mg), In- Vivo Bioequivalence in Iranian healthy volunteers.IRCT20200105046010N4Tabriz University of Medical Sciences24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mgIRCT20200105046010N96???? ????? ?????24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg..IRCT20200105046010N99Kharazmi Company24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg tabletIRCT20200623047902N36Actover Co.24